Putting an end to the rumors, China's WuXi PharmaTech, the country's largest CRO, has announced plans for a $120 million IPO on the New York Stock Exchange. The U.S. offering was spurred in part by the fact that most of the company's revenue is coming from American companies. Founded six years ago, WuXi has been growing fast as China takes a central place in the drug development world.
- read the report on the IPO from DrugResearcher.com
ALSO: Cambridge, MA-based Archemix, a 2007 Fierce 15 winner, has filed an IPO designed to raise $69 million. Banc of America Securities and Bear Stearns are serving as co-lead underwriters in the IPO for Archemix, which has raised $132 million in venture funds in the last six years. Report
Related Articles:
CRO market hits $14B. Report
Asian CRO gains $22M in second round. Report